Resistance to third-generation cephalosporins in Escherichia coli in the French community: The times they are a-changin'?

• Published in: International journal of antimicrobial agents 2020-05, Vol.55 (5), p.105909-105909, Article 105909
• Main Authors: Jeanvoine, Audrey, Bouxom, Hélène, Leroy, Joel, Gbaguidi-Haore, Houssein, Bertrand, Xavier, Slekovec, Céline
• Format: Article
• Language: English
• Subjects: Anti-Bacterial Agents - therapeutic use; beta-Lactamases - genetics; Cephalosporins - therapeutic use; Ciprofloxacin - therapeutic use; Drug Resistance, Bacterial - genetics; Escherichia coli; Escherichia coli - drug effects; Escherichia coli - genetics; Escherichia coli - isolation & purification; Escherichia coli Infections - drug therapy; Escherichia coli Infections - epidemiology; France - epidemiology; Humans; Life Sciences; Microbial Sensitivity Tests; Microbiology and Parasitology; Nalidixic Acid - therapeutic use; Outpatients; Outpatients - statistics & numerical data; Prevalence; Quinolones; Resistance; Retrospective Studies; Third-generation cephalosporins
• ISSN: 0924-8579; 1872-7913
• DOI: 10.1016/j.ijantimicag.2020.105909

•Third-generation cephalosporin (3GC) resistance of community E. coli significantly decreased in France from 2015 to 2017.•3GC and quinolone consumption significantly decreased in the French community.•Reducing antibiotic consumption is not instantly followed by a decrease in antimicrobial resistance. Since the early 2000s, Escherichia coli resistance to third-generation cephalosporins (3GCs) has been increasing in all European countries, mainly due to the spread of extended spectrum β-lactamases (ESBLs). Here we present a retrospective study that combines resistance of E. coli to 3GCs and quinolones with data on antibiotic use in the community in a region of Northeastern France. Since 2012, an observational surveillance of antimicrobial resistance and antibiotic use in the community was conducted: data on antimicrobial resistance in E. coli isolates were collected from 11 private laboratories, and consumption data were collected from the three main healthcare insurances. A significant decrease in the prevalence of resistance to 3GCs (from 5.6% to 4.2%; P < 0.001), nalidixic acid (from 16.7% to 14.8%; P = 0.004) and ciprofloxacin (from 10.9% to 8.1%; P < 0.001) was reported between 2015 and 2017. Although total antibiotic consumption did not vary significantly between 2012 and 2017, a decrease in the consumption of 3GCs (–32.%; P < 0.001) and quinolones (–25.5%; P < 0.001) was observed. Here we report a decrease in the prevalence of E. coli isolates resistant to 3GCs and quinolones in outpatients in the context of significant decreasing consumption of these two antibiotic classes.